XML 175 R26.htm IDEA: XBRL DOCUMENT v3.20.1
ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Dec. 31, 2018
Organization And Summary Of Significant Accounting Policies [Line Items]        
Increase in revenues $ 13,076 $ 8,071    
Decrease in net loss 42,974 42,203    
Letter of credit established as a deposit 1,500      
Cash and cash equivalents 85,749 80,968 $ 80,428 $ 140,418
Non-current restricted cash 1,500 3,500 1,500 3,500
Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows 87,249 84,468 $ 81,928 $ 143,918
Kite Pharma Inc        
Organization And Summary Of Significant Accounting Policies [Line Items]        
Increase in revenues $ 7,219 $ 8,312    
Kite Pharma Inc | Customer Concentration Risk | Revenue from Contract with Customer        
Organization And Summary Of Significant Accounting Policies [Line Items]        
Percentage of revenues 55.00% 75.00%    
Pfizer | Customer Concentration Risk | Revenue from Contract with Customer        
Organization And Summary Of Significant Accounting Policies [Line Items]        
Percentage of revenues 27.00%      
Sanofi        
Organization And Summary Of Significant Accounting Policies [Line Items]        
Increase in revenues $ 499 $ 1,949    
Sanofi | Customer Concentration Risk | Revenue from Contract with Customer        
Organization And Summary Of Significant Accounting Policies [Line Items]        
Percentage of revenues 4.00% 18.00%    
Change in Collaboration Agreement Scope | Collaboration Agreement | Pfizer        
Organization And Summary Of Significant Accounting Policies [Line Items]        
Increase in revenues $ 100      
Decrease in net loss $ 100